Morphosys said it has agreed to a three-year extension of its ongoing research partnership with Japanese pharma firm Shionogi.
The agreement covers Shionogi's use of Morphosys' HuCal antibody platform for drug development research in exchange for annual user fees. Further financial details were not disclosed.
The project will be run on Morphosys' end by its AbD Serotec unit. Shionogi will have the right to use the company's HuCAL Platinum antibody library for research purposes at one of its research sites.